טוען...
Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
BACKGROUND: Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of non-Hodgkin’s lymphoma, which has an aggressive clinical course and an extremely poor prognosis. Chidamide is a novel, orally active, benzamide-type histone deacetylase (HDAC) inhibitor that has been used for peripheral T-cell ly...
שמור ב:
| הוצא לאור ב: | World J Clin Cases |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Baishideng Publishing Group Inc
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7385602/ https://ncbi.nlm.nih.gov/pubmed/32775395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i14.3122 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|